Next Article in Journal
Management of Dyspnea in Palliative Care
Previous Article in Journal
Willingness of Women with Early Estrogen Receptor–Positive Breast Cancer to Take Adjuvant CDK4/6 Inhibitors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 3
10.3747/co.27.5731
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck

by
M. Valdes
1,*,
J. Villeda
2,
H. Mithoowani
1,
T. Pitre
1 and
M. Chasen
3
1
McMaster University and Grand River Regional Cancer Centre, Kitchener, ON, Canada
2
Carman Community Health Centre, Carman, MB, Canada
3
William Osler Health System–Brampton Civic Hospital, Brampton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(3), 135-141; https://doi.org/10.3747/co.27.5731
Submission received: 1 March 2020 / Revised: 1 April 2020 / Accepted: 1 May 2020 / Published: 1 June 2020

Abstract

Background: Multiple immunologic parameters have provided useful prognostic and assessment significance in various cancers, including head-and-neck squamous cell carcinoma (scc). We sought to identify whether pretreatment inflammatory markers could prognosticate recurrence in patients with advanced (stage III or IV) head-and-neck scc who underwent therapy with curative intent in a tertiary care centre between January 2010 and December 2012. Methods: In a chart review, we recorded demographics; primary tumour characteristics; p16 status; pretreatment inflammatory markers, including body mass index (bmi), neutrophil-to-lymphocyte ratio (nlr), C-reactive protein (crp), and serum albumin; therapy received; and date of relapse, death, or last follow-up. The main outcome was relapse-free survival (rfs). Overall survival (os) was a secondary outcome. Results: From among 235 charts reviewed, 118 cases were included: 86 oropharyngeal (50 p16-positive, 18 p16-negative, 17 p16 unavailable, 1 p16 indeterminate), and 32 non-oropharyngeal (7 p16-positive, 19 p16-negative, 6 p16 unavailable). Median follow-up was 2.45 years (25%–75% interquartile range: 1.65–3.3 years). In univariate analysis, p16 status, bmi, modified Glasgow prognostic score, and crp were significant for rfs, but in multivariate analysis, only p16 status, bmi, and crp remained significant. For os, only crp and nlr were significant in both the univariate and multivariate analyses. After adjustment for p16 status, nlr did not remain significant. After adjustment for p16 status, crp remained significant for both rfs and os. Conclusions: In patients with head-and-neck scc, a stronger prognostic value is associated with human papillomavirus status than with nlr and many other factors, including bmi and albumin. However, even though few of our patients had high crp, serum crp remained significant despite p16-positive status.
Keywords: head-and-neck cancer; squamous cell carcinoma; C-reactive protein; nlr; hpv head-and-neck cancer; squamous cell carcinoma; C-reactive protein; nlr; hpv

Share and Cite

MDPI and ACS Style

Valdes, M.; Villeda, J.; Mithoowani, H.; Pitre, T.; Chasen, M. Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck. Curr. Oncol. 2020, 27, 135-141. https://doi.org/10.3747/co.27.5731

AMA Style

Valdes M, Villeda J, Mithoowani H, Pitre T, Chasen M. Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck. Current Oncology. 2020; 27(3):135-141. https://doi.org/10.3747/co.27.5731

Chicago/Turabian Style

Valdes, M., J. Villeda, H. Mithoowani, T. Pitre, and M. Chasen. 2020. "Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck" Current Oncology 27, no. 3: 135-141. https://doi.org/10.3747/co.27.5731

Article Metrics

Back to TopTop